Cite
HARVARD Citation
Zhou, C. et al. (2022). Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet oncology. 23 (2), pp. 220-233. [Online].